How Vityl Actyv Works
Vitamin B9 (folate) has extensive actions in the human body, with research showing it is necessary for a multitude of vital processes, such as supporting healthy DNA synthesis, healthy homocysteine metabolism, nervous system support, promoting energy production, and more.1
Unfortunately, the folic acid found in food and many nutritional supplements needs to go through several enzymatic conversions to be converted to its bioactive form L-5-MTHF (and not everyone is able to properly metabolize dietary folic acid into L-5-MTHF).2
As such, supplementing with L-5-MTHF and other methylation- supporting nutrients, like betaine HCl, N-acetyl-L-cysteine (NAC), and methylcobalamin (vitamin B12) can support cardiovascular health by encouraging healthy homocysteine metabolism. Folate also works along other B vitamins and minerals in Vityl Actyv to promote healthy DNA function, as well as support healthy hemoglobin function—a protein found in red blood cells that transports oxygen and carbon dioxide throughout the body.
Vityl Actyv Supplementation
Research cited herein suggests that the nutrients in Vityl Actyv play key roles in methylation processes within the body, especially in the regeneration of methionine from homocysteine. In turn, these nutrients help support a variety of biological processes that are vital to health and longevity.
To summarize, the most pertinent research-backed benefits of supplementation with Vityl Actyv may include:
- Supports methylation and homocysteine metabolism
- Supports cardiovascular function and energy production
- Supports cognitive function and healthy mood
- Helps promote healthy DNA function
- Helps metabolize amino acids
1. Lucock, M. (2000). Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Molecular genetics and metabolism, 71(1), 121-138.
2. Blom, H. J., & Smulders, Y. (2011). Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. Journal of inherited metabolic disease, 34(1), 75-81.